TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01165216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab, 3 mg
Description: Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab, 10 mg
Description: IV injection, administered every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
Study: NCT02861885

Intervention type: OTHER
Intervention: Chromoendoscopy
Description: Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
Study: NCT02844868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
Study: NCT03756324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHPM (Chinese Herbal Patent Medicine )
Description: Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHPM (Chinese Herbal Patent Medicine )
Description: Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics Cefdinir Capsules
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics Cefdinir Capsules
Description: Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
Study: NCT03801057

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MPH_active
Description: One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MPH_placebo
Description: One daily intake at breakfast of supplementary placebo, a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
Study: NCT04765319

Intervention type: BEHAVIORAL
Intervention: CPT for PTSD
Description: Evidence based psychotherapy for PTSD
Study: NCT02422199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT03124004

Intervention type: PROCEDURE
Intervention: periodontal debridement
Description: with ultrasonic device supragingival and subgingival full-mouth debridement is provided

Intervention type: PROCEDURE
Intervention: periodontal debridement
Description: with ultrasonic device supragingival and subgingival full-mouth debridement is provided
Study: NCT03711695

Intervention type: DEVICE
Intervention: iBeat wristwatch device
Description: The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.

Intervention type: DEVICE
Intervention: iBeat wristwatch device
Description: The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.

Intervention type: DEVICE
Intervention: iBeat wristwatch device
Description: The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
Study: NCT01077050

Intervention type: DEVICE
Group type: OTHER
Intervention: SciBase III Electrical Impedance Spectrometer
Description: SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
Study: NCT03007225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trans-arterial chemoembolization (TACE)
Description: TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE with Drug Eluting Beads procedure
Description: The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan).
Study: NCT02685267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study: NCT04562428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiang Sha Liu Jun Zi Decoction dry powder
Description: the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XSLJZ Placebo
Description: XSLJZ Placebo
Study: NCT03254589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: See arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: See arm descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other DMARDs
Description: See arm
Study: NCT03965390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral education
Description: Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health
Study: NCT01136980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIF Transoral Fundoplication
Description: A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham placebo procedure
Description: The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
Study: NCT02118441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Radial Artery Catheter Insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Palpation-guided Radial Artery Catheter insertion
Study: NCT01495806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucomannan
Description: 2 x 5g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: glucose 5 g
Study: NCT02699424

Intervention type: RADIATION
Group type: OTHER
Intervention: External radiation therapy
Study: NCT02336529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study: NCT02876549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine 0.25 mg/kg/day
Description: 0.25 mg/kg/day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine 0.75 mg/kg weekly
Description: 0.75 mg/kg weekly for eight weeks
Study: NCT01610934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
Study: NCT02259335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal CO2 removal device
Description: A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
Study: NCT00354978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m\^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m\^2 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m\^2 by vein over 90 minutes on Day 1 of 14 day cycle.
Study: NCT01079052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Tablets
Study: NCT05504785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DexCom G6 continuous glucose monitor
Description: Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DexCom G6 continuous glucose monitor
Description: Use of real-time DexCom G6 continuous glucose monitor (CGM or glucose sensor) trend data and an insulin-dosing algorithm to control the glucose levels of diabetic patients undergoing hip/knee orthopedic surgery at Thomas Jefferson University Hospital (TJUH).
Study: NCT02194478

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meditation
Description: 30 minute, 8 week meditation
Study: NCT03176706

Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION

Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION

Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION

Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION

Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION

Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION

Intervention type: OTHER
Intervention: no intervention
Description: this is a completely observational study, NO INTERVENTION
Study: NCT02784691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feeligreen patch
Study: NCT00080444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: aprepitant capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: aprepitant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: ondansetron IV preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron IV preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron IV preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to aprepitant
Description: Matching placebo to aprepitant capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to dexamethasone
Description: Matching placebo to dexamethasone tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to dexamethasone
Description: Matching placebo to dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue medication
Description: Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rescue medication
Description: Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rescue medication
Description: Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
Study: NCT03843554

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Oral Hygiene
Description: Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral mucosal deterging and dental prophylaxis
Description: Subjects will receive a professional dental prophylaxis including periodontal surface debridement \[a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum\] and deterging of the oral mucosal surfaces.
Study: NCT03714152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: 5 mg or 25 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABI-H2158
Description: Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
Study: NCT02169427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC
Description: The drug substance of 100 mg OPC was administered as 1 capsule.
Study: NCT04002492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bodyweight training
Description: Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
Study: NCT00214201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor withdrawal
Description: stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
Study: NCT03944317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine
Description: SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks